<DOC>
	<DOCNO>NCT00645099</DOCNO>
	<brief_summary>The purpose 6 month study compare metabolic effect paliperidone ER olanzapine patient schizophrenia , use ratio concentration lipid ( triglyceride ( TG ) ) blood concentration good cholesterol ( high density lipoprotein ( HDL ) ) blood primary parameter . Approximately 456 adult patient participate study .</brief_summary>
	<brief_title>A 6 Month Study Compare Metabolic Effects Paliperidone ER Olanzapine Patients With Schizophrenia</brief_title>
	<detailed_description>This prospective randomized ( study medication assign change ) open-label , parallel-group , multicenter , 6 month study compare metabolic effect paliperidone ER olanzapine patient schizophrenia use ratio concentration lipid ( triglyceride ) blood concentration good cholesterol ( high density lipoprotein ( HDL ) ) primary parameter . Secondary objective include evaluation additional parameter related total action body keep alive ( metabolic endpoint ) demonstration non-inferiority paliperidone ER versus olanzapine efficacy measure Positive Negative Syndrome Scale ( PANSS ) . Patients previously treat oral antipsychotic , except treat paliperidone ER , olanzapine clozapine last 6 month , enrol treat paliperidone ER ( 6 9 mg/day ) olanzapine ( 10 15 mg/day ) . Patients divide group accord metabolic effect previous antipsychotic medication ( medication increase body weight vs. medication increase body weight ) . Throughout study flexible dosing allow base investigator discretion . A study treatment period 6 month plan patient . Medication treat symptom like confusion , blur vision , constipation , dry mouth , light-headedness , difficulty start continue urinate , loss bladder control may continue four week taper discretion investigator . Approximately 456 adult patient ( 228 treatment group ) participate study . Efficacy assess follow measure : PANSS ( total score subscale score ) , Clinical Global Impression - Severity ( CGI-S ) , Self-rated health status Survey SF-36 , Sleep daytime drowsiness evaluation scale . The parameter related total action body keep alive ( metabolic endpoint ) assess follow : ratio blood lipid blood good cholesterol concentration ( TG : HDL ratio ) ( primary evaluation , plasma fasting lipid good cholesterol concentration measure ) , fast plasma insulin fast plasma glucose , plasma glucose insulin concentration 75 gram oral glucose tolerance test ( OGTT ) asses insulin sensitivity change insulin secretion , fast good cholesterol , lipid , glucose level determination new onset presence metabolic syndrome treatment accord criterion Third Report National Cholesterol Education Program Expert Panel Detection , Evaluation , Treatment High Blood Cholesterol Adults ( NCEP/ATPIII criterion ) , weight , Body-Mass-Index waist circumference determination new onset presence medical condition associate abdominal obesity , abnormality glucose , lipid cholesterol metabolism , elevate blood pressure increase risk cardiovascular disease type 2 diabetes ( metabolic syndrome ) treatment accord NCEP/ATP III criterion . All patient receive trial medication ( paliperidone ER olanzapine ) least included analysis demographic baseline characteristic data . 2 dosage level paliperidone ER ( 6 9mg per day ) 2 olanzapine ( 10 15mg per day ) available patient . Throughout study flexible dosing allow base investigator 's discretion . Study medication take morning orally , water . A study treatment period 6 month plan patient .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patient meet DSMIV criterion schizophrenia Patient PANSS total score screen 60 100 , inclusive Patient must , opinion investigator , benefit treatment paliperidone ER olanzapine Patients lipidlowering therapy must stable dose least 4 week statin , niacin , ezetimibe resin least 12 week fibrates Female patient must postmenopausal ( least 1 year ) , surgically sterile , abstinent , , sexually active , practice effective method birth control ( e.g . prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study Women childbearing potential must negative urine pregnancy test screen Patient healthy basis physical examination vital sign screen Patient previously treat paliperidone ER , olanzapine , clozapine within past 6 month never treat antipsychotic Treatment depot antipsychotic within past 3 month Treatment mood stabilizer recently initiate antidepressant ( &lt; = 3 month ) Patient abnormal fasting plasma glucose ( &gt; 126 mg/dL ) fast triglyceride ( TG ) level ( &gt; 400 mg/dL ) screen Relevant history significant and/or unstable cardiovascular , respiratory , neurologic ( include seizure significant cerebrovascular ) , renal , hepatic , endocrine , immunologic disease , include recent present clinically relevant laboratory abnormality ( deem investigator ) History current symptom tardive dyskinesia History neuroleptic malignant syndrome Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Paliperidone ER</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>